Outcomes from NATALEE and MonarchE

EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

Now Viewing

EP: 3.Outcomes from NATALEE and MonarchE

EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following:

• (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
  • How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
• (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
  • Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
  • Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.